Floatz logo

Leflunomide

Symptomatic COVID-19 Infection Laboratory-Confirmed

City of Hope Medical CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Symptomatic COVID-19 Infection Laboratory-Confirmed cohort.

Asset / SponsorPhaseRating
RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN (CANSINO BIOLOGICS)
Seventh Medical Center of PLA General Hospital
Phase 3BBB
Genotropin
ClinAmygate
Phase 4BB
cc-220
Nguyen Thi Trieu, MD
Phase 4BB
Tocilizumab
National Cancer Institute (NCI)
Phase 3BB
Genotropin
ClinAmygate
Phase 4BB

View all 50 →

Same molecule, other indications

Leflunomide is also rated in:

immunoglobulin G4-related sclerosing diseaseDormant
BB
Indicative ·
69 / 100
View asset →
central nervous system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →